FDA firms up JAK inhibitor warnings after Xeljanz reviewThe FDA has concluded its safety review of Pfizer’s JAK inhibitor Xeljanz and Xeljanz XR, requiring revised warnings Share XFDA firms up JAK inhibitor warnings after Xeljanz reviewhttps://pharmaphorum.com/news/fda-firms-up-jak-inhibitor-warnings-after-xeljanz-review/
Trials leave Galapagos’ SIK programme looking under the weatherGalapagos has had to send its SIK inhibitor programme back to the drawing board after its lead compound Share XTrials leave Galapagos’ SIK programme looking under the weatherhttps://pharmaphorum.com/news/trials-leave-galapagos-sik-programme-looking-under-the-weather/
FDA holds back from action over Xeljanz safety studyThe FDA has said it will wait for additional results from last week’s trial showing an increased risk Share XFDA holds back from action over Xeljanz safety studyhttps://pharmaphorum.com/news/fda-holds-back-from-action-over-xeljanz-safety-study/
NICE backs broad use for Gilead/Galapagos arthritis pill JyselecaPatients with rheumatoid arthritis (RA) in England will be able to get treatment with Gilead Sciences and Galapagos’ Share XNICE backs broad use for Gilead/Galapagos arthritis pill Jyselecahttps://pharmaphorum.com/news/nice-backs-broad-use-for-gilead-galapagos-arthritis-pill-jyseleca/
Gilead’s rheumatoid arthritis pill approved in JapanGilead has scored a major approval for its troubled rheumatoid arthritis pill filgotinib, after regulators in Japan granted Share XGilead’s rheumatoid arthritis pill approved in Japanhttps://pharmaphorum.com/news/gileads-rheumatoid-arthritis-pill-approved-in-japan/
Holistic immunology: Supporting patients at every stage of their journeyAs part of our series from leaders at Janssen, the company’s Max Pahlow looks at how approaches to Share XHolistic immunology: Supporting patients at every stage of their journeyhttps://pharmaphorum.com/r-d/views-analysis-r-d/holistic-immunology-supporting-patients-at-every-stage-of-their-journey/
Analysts question Gilead’s commitment to arthritis drug after FDA setbackThe FDA has rejected Gilead and Galapagos’ rheumatoid arthritis (RA) pill filgotinib over concerns that it could damage Share XAnalysts question Gilead’s commitment to arthritis drug after FDA setbackhttps://pharmaphorum.com/news/gilead-could-become/
Breaking policy and perceptual barriers: BiosimilarsExperts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted Share XBreaking policy and perceptual barriers: Biosimilarshttps://deep-dive.pharmaphorum.com/magazine/market-access-2020/breaking-policy-and-perceptual-barriers-biosimilars/
ICER says ‘marginal’ benefits for AbbVie’s new RA drugAbbVie’s Rinvoq rheumatoid arthritis drug is an important part of the company’s strategy to replace lost sales as Share XICER says ‘marginal’ benefits for AbbVie’s new RA drughttps://pharmaphorum.com/news/icer-says-marginal-benefits-for-abbvies-new-ra-drug/
